BRD4 and plasma cell myeloma: Furthermore, transcription of c-Myc, controlled by the epigenetic regulator, BRD4, and inhibition of BRD4 by the small molecule inhibitor, JQ1, showed potent anti-cancer activity in vitro and in vivo of several cancers, for example, multiple myeloma, AML and Burkitt’s lymphoma [87,88,89,90].